Psychiatric and somatic markers of anxiety: Identification and pharmacologic treatment

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 2, Issue 2, 2000, Pages 49-54

  Gelenberg, Alan J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0242614126     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v02n0204     Document Type: Article

References (57)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
2. Martin LM, Fleming KC, Evans JM. Recognition and management of anxiety and depression in etderjy patients. Mayo Clin Proc 1995;70: 999-1006
3. Burke WJ, Folks DG, McNeilly DP. Effective use of anxiolytics in older adults. Clin Geriatr Med 1998;14:47-65
4. Small GW. Recognizing and treating anxiety in the elderly. J Clin Psychiatry 1997;58(suppl 3):41-47
5. DuPont RL, Rice DP, Miller LS, et al. Economic costs of anxiety disorders. Anxiety 1996;2:167-172
6. Nisenson LG, Pepper CM, Schwenk TL, et al. The nature and prevalence of anxiety disorders in primary care. Gen Hosp Psychiatry 1998;20:21-28
7. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United-Stales: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
8. Flint AJ. Epidemiology and comorbidity of anxiety disorder? in the elderly Am J Psychiatry 1994;151:640-649
9. Schapira K, Roth M, Kerr TA, et al. The prognosis of affective disorders: the differentiation of anxiety states from depressive illnesses. Br J Psychiatry 1972; 121:175-181
10. Keller MB, Hanks DL. Anxiety symptom relief in depression treatment outcomes. J Clin Psychiatry 1995;56(suppl 6):22-29
11. Baughman OL III. Rapid diagnosis and treatment of anxiety and depression in primary care: the somatizing patient. J Fam Pract 1994;39:373-378
12. Katon WJ, Walker EA. Medically unexplained symptoms in primary care. J Clin Psychiatry 1998;59(suppl 20):15-21
13. Zajecka J. Importance of establishing the diagnosis of persistent anxiety. J Clin Psychiatry 1997;58(suppl 3):9-13
14. Kroenke K, Mangelsdorff AD. Common symptoms in ambulatory care: incidence, evaluation, therapy, and outcome. Am J Med 1989;86:262-266
15. Kroenke K, Spitzer RE, Williams JBW, et al. Physical symptoms in primary care: predictors of psychiatric disorders and functional impairment. Arch Fam Med 1994;3:774-779
16. Ormel J, Koeter MWJ, van den Brink W, et al. Recognition, management, and course of anxiety and depression in general practice. Arch Gen Psychiatry 1991;48:700-706
17. Bridges KW, Goldberg DP. Somatic presentation of DSM-III psychiatric disorders in primary care. J Psychosom Res 1985;29:563-569
18. Kirmayer EJ, Robbins JM, Dworkind M, et al. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993;150:734-741
19. Brown C, Schulberg HC, Madonia MJ, et al. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry 1996;153:1293-1300
20. Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety 1996/1997;4:160-168
21. Rogers MP, White K, Warshaw MG, et al. Prevalence of medical illness in patients with anxiety disorders. Int J Psychiatry Med 1994;24:83-96
22. Simon G, Ormel J, VonKorff M, et al. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 1995; 152:352-357
23. Rice DP, Miller LS. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry 1998; 173 (suppl 34):4-9
24. Katon W, VonKorff M, Lin E, et al. Distressed high utilizers of medical care: DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry 1990;12:355-362
25. Souêtre E, Lozet H, Cimarosti I, et al. Cost of anxiety disorders: impact of comorbidity. J Psychosom Res 1994;38(suppl 1):151-160
26. Dubovsky SL. Generalized anxiety disorder: new concepts and psychopharmacologie therapies. J Clin Psychiatry 1990;51(1, suppl):3-10
27. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398-1405
28. Schweizer E, Rickels K. Strategies for treatment of generalized anxiety in the primary care setting. J Clin Psychiatry 1997;58(suppl 3):27-31
29. Schweizer E. Generalized anxiety disorder: longitudinal course and pharmacologie treatment. Psychiatr Clin North Am 1995;18:843-857
30. Sussman N. The uses of buspirone in psychiatry. J Clin Psychiatry Monograph 1994;12(1):3-19
31. Sramek JJ, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry 1996;57:287-291
32. Jefferson JW. Antidepressants in panic disorder. J Clin Psychiatry 1997;58 (suppl 2):20-25
33. Tollefson GD, Holman SL, Sayler ME, et al. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 1994;55:50-59
34. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993;50: 884-895
35. Sheehan DV, Harnett-Sheehan K. The role of SSRIs in panic disorder. J Clin Psychiatry 1996;57(suppl 10):51-58
36. Sheehan D, Dunbar GC, Fuell DL. The effect of paroxetine on anxiety and agitation associated with depression. Psychopharmacol Bull 1992;28: 139-143
37. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995; 152:1368-1376
38. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997;95:444-450 39.
39. Kuzel RJ. Treating comorbid depression and anxiety. J Earn Pract 1996;43(6, suppl):S45-S53
40. Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull 1995;31: 767-771
41. Pollack MH, Worthington JJ III, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996;32:667-670
42. Geracioti TD Jr Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry 1995;56:408-410 43.
43. Zajecka JM, Fawcett J, Guy C. Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine [letter]. J Clin Psychopharmacol 1990:;10:152-153
44. Khan A, Upton GV, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychophatmacol 1998;18:19-25
45. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997;72:835-847
46. Sussman N. Treatment of anxiety with buspirone.''Psychiatr Ann 1987;17: 114-117,120
47. Nemeroff CB. Evolutionary trends in the pharmacotherapeutic management of depression. J Clin Psychiatry 1994;55(12, suppl):3-15
48. Davidson JRT, DuPont RL, Hedges D, et al. Efficacy, safely, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999;60:528-535
49. Hackett D, Parks V, Salinas E. A 6-month evaluation of 3 dose levels of venlafaxine extended-release in non-depressed outpatients with generalized anxiety disorder [poster]. Presented at the 19th annual conference of the Anxiety Disorders Association of America; March 25-28, 1999; San Diego, Calif
50. Haskins JT, Rudolph R, Aguiar L, et al. Venlafaxine XR is an efficacious short- and long-term treatment for generalized anxiety disorder [poster]. Presented at the 11th annual Congress of the European College of Neuropsychopharmacology; Oct 31-Nov4, 1998; Paris, France
51. Haskins T, Rudolph R, Pallay A, et al. Double-blind, placebo-controlled study of once daily venlafaxine XR in outpatients with generalized anxiety disorder (GAD) [poster]. Presented at the 21 st annual meeting of the Col-legium Internationale Neuro-Psychopharmacologicum; July 12-16, 1998; Glasgow, Scotland
52. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16(3, suppl 2):37S-53S
53. Hedges DW, Reimherr FW, Strong RE, et al. An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol Bull 1996;32:671-676
54. Ballenger JC. Clinical evaluation of venlafaxine. J Clin Psychopharmacol 1996;16(3, suppl 2):29S-36S
55. Thase ME, for the Venlafaxine XR 209 Study Group. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry 1997;58:393-398
56. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988;49:293-301
57. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998;47:55-62